financetom
Business
financetom
/
Business
/
Rambus Insider Sold Shares Worth $932,586, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rambus Insider Sold Shares Worth $932,586, According to a Recent SEC Filing
Mar 6, 2024 10:51 AM

01:31 PM EST, 03/06/2024 (MT Newswires) -- Luc Seraphin, Director, President and CEO, on March 05, 2024, sold 15,000 shares in Rambus ( RMBS ) for $932,586. Following the Form 4 filing with the SEC, Seraphin has control over a total of 304,755 shares of the company, with 304,755 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/917273/000091727324000034/xslF345X03/wk-form4_1709749611.xml

Price: 64.02, Change: +2.62, Percent Change: +4.27

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BMO Says Ontario's Provincial Finances Are Improving
BMO Says Ontario's Provincial Finances Are Improving
Oct 31, 2024
07:21 AM EDT, 10/31/2024 (MT Newswires) -- The Canadian province of Ontario is projecting a C$6.6 billion deficit for FY24/25 or roughly 0.6% of gross domestic product, notably smaller than the C$9.8 billion shortfall estimated in the initial budget plan, noted Bank of Montreal (BMO). Considering that the mid-year fiscal update came with a strong dose of new spending measures...
Regeneron beats results estimates on demand for eczema treatment, eye drug
Regeneron beats results estimates on demand for eczema treatment, eye drug
Oct 31, 2024
Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals ( REGN ) beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea. Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash...
Estee Lauder Fiscal Q1 Adjusted Earnings Rise, Net Sales Fall; Fiscal Q2 Guidance Issued; Dividend Cut
Estee Lauder Fiscal Q1 Adjusted Earnings Rise, Net Sales Fall; Fiscal Q2 Guidance Issued; Dividend Cut
Oct 31, 2024
07:21 AM EDT, 10/31/2024 (MT Newswires) -- Estee Lauder ( EL ) reported fiscal Q1 adjusted earnings Thursday of $0.14 per diluted share, up from $0.11 a year earlier. Analysts polled by Capital IQ expected $0.10. Net sales for the quarter ended Sept. 30 were $3.36 billion, down from $3.52 billion a year earlier. Analysts surveyed by Capital IQ expected...
Uber Technologies' Q3 Earnings, Revenue Increase
Uber Technologies' Q3 Earnings, Revenue Increase
Oct 31, 2024
07:21 AM EDT, 10/31/2024 (MT Newswires) -- Uber Technologies ( UBER ) reported Q3 earnings Thursday of $1.20 per diluted share, up from $0.10 a year earlier. Analysts polled by Capital IQ expected $0.41. Revenue for the quarter ended Sept. 30 was $11.19 billion, compared with $9.29 billion a year earlier. Analysts polled by Capital IQ expected $10.98 billion. Price:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved